QSAR analysis of 2-benzoxazolyl hydrazone derivatives for anticancer activity and its possible target prediction

Medicinal Chemistry Research

Volumn 21, Issue 2, 2012, Pages 133-144

  Narayana Moorthy, N S Hari ^a   Cerqueira, Nuno S ^a   Ramos, Maria J ^a   Fernandes, Pedro A ^a  

^a UNIVERSITY OF PORTO   (Portugal)

Author keywords

2 Benzoxazolyl hydrazone; Cancer; QSAR; Ribonucleotide reductase; Vsurf descriptors

Indexed keywords

2 BENZOXAZOLYL HYDRAZONE DERIVATIVE; ANTINEOPLASTIC AGENT; HYDRAZONE DERIVATIVE; IRON COMPLEX; RIBONUCLEOTIDE REDUCTASE; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING SITE; BIOLOGICAL ACTIVITY; BURKITT LYMPHOMA; CANCER CELL CULTURE; HELA CELL; HUMAN; HUMAN CELL; HYDROGEN BOND; HYDROPHOBICITY; IC 50; QUANTITATIVE STRUCTURE ACTIVITY RELATION;

EID: 84861888793     PISSN: 10542523     EISSN: 15548120     Source Type: Journal    
DOI: 10.1007/s00044-010-9510-3     Document Type: Article

References (45)

1. Agrawal VK, Srivastava R, Khadikar PV (2001) QSAR studies on some antimalarial sulfonamides. Bioorg Med Chem 9: 3287-3293
2. 2. J Mol Graphs Model 20:269-276
3. Balaji S, Karthikeyan C, Moorthy NSHN, Trivedi P (2004) QSAR modelling of HIV-1 reverse transcriptase inhibition by benzoxazinones using a combination of P-VSA and pharmacophore feature descriptors. Bioorg Med Chem Lett 14:6089-6094 (Pubitemid 39531278)
4. Balasubramanian N, Avinash D, Vishnukant M (2007) QSAR studies of 4,5-dihydro-4-oxo-3H-imidazo[4,5-c]pyridines as potent angiotensin II receptor antagonists by MLR and NLR analysis. ARKIVOC i:189-204
5. Cerqueira NM, Pereira S, Fernandes PA, Ramos MJ (2005a) Overview of ribonucleotide reductase inhibitors: an appealing target in anti-tumor therapy. Curr Med Chem 12:1283-1294 (Pubitemid 40711424)
6. Cerqueira NMFSA, Pereira S, Fernandes PA, Ramos MJ (2005b) Overview of ribonucleotide reductase inhibitors: an appealing target in anti-tumour therapy. Curr Med Chem 12(11):1283-1294 (Pubitemid 40711424)
7. Cerqueira NMFSA, Fernandes PA, Ramos MJ (2006) Enzyme ribonucleotide reductase: unraveling an enigmatic paradigm of enzyme inhibition by furanone derivatives. J Phys Chem B 110(42): 21272-21281 (Pubitemid 44797402)
8. Cerqueira NMFSA, Fernandes PA, Ramos MJ (2007a) Ribonucleotide reductase: a critical enzyme for cancer chemotherapy and antiviral agents. Recent Pat Anticancer Drug Discov 2:11-29 (Pubitemid 46723151)
9. Cerqueira NMFSA, Fernandes PA, Ramos MJ (2007b) Understanding ribonucleotide reductase inactivation by gemcitabine. Chem Eur J 13(30):8507-8515 (Pubitemid 47608884)
10. Chem BioOffice (2008) CambridgeSoft Corp, UK
11. Cook RD (1979) Influential observation in linear regression. J Am Stat Assoc 74(365):169-174
12. Cruciani G, Crivori P, Carrupt PA, Testa B (2000a) Molecular fields in quantitative structure permeation relationships: the Volsurf approach. J Mol Struct Theochem 503(1-2):17-30
13. Cruciani G, Pastor M, Guba W (2000b) Volsurf: a new tool for the pharmacokinetic optimization of lead compounds. Eur J Pharm Sci 11(2):S29-S39
14. Das A, Trousdale MD, Ren SJ, Lien EJ (1999) Inhibition of herpes simplex virus type 1 and adenovirus type 5 by heterocyclic Schiff bases of aminohydroxyguanidine tosylate. Antiviral Res 44:201-208 (Pubitemid 30017947)
15. Durbin J, Watson GS (1950) Testing for serial correlation in least squares regression, I. Biometrika 37:409-428
16. Durbin J, Watson GS (1951) Testing for serial correlation in least squares regression, II. Biometrika 38:159-179
17. Easmon J, Purstinger G, Thies KS, Heinisch G, Hofmann J (2006) Synthesis, structure-activity relationship and antitumor studies of 2-benzoxazolyl hydrazones derived from alpha-(N)-acyl heteroatoms. J Med Chem 49:6343-6350 (Pubitemid 44595211)
18. Erikkson L, Jaworsha J, Worth AP, Mark TDC, Robert MM, Gramatica P (2003) Methods for reliability and uncertainty assessment and for applicability evaluation of classification and regression based QSARs. Environ Health Perspect 111:1361-1375 (Pubitemid 37021142)
19. Erol E, Hasan T, Semra G, Selami P, Oral O (2007) A DFT-based QSARs study of acetazolamide/sulfanilamide derivatives with carbonic anhydrase (CA-II) isozyme inhibitory activity. Int J Mol Sci 8:145-155
20. Fernandes PA, RamosMJ (2003) Theoretical studies on themechanismof inhibition of ribonucleotide reductase by (E)-2′-fluromethylene-2′- deoxycitidine-5′-diphosphate. J Am Chem Soc 125(20):6311-6322 (Pubitemid 36583006)
21. Finch RA, Liu M, Grill SP, Rose WC, Loomis R, Vasquez KM, Cheng Y, Sartorelli AC (2000) Triapine (3-aminopyridine-2-carboxaldehyde-thiosemicarba- zone): a potent inhibitor of ribonucleotide reductase activity with broad-spectrum antitumor activity. Biochem Pharmacol 59:983-991 (Pubitemid 30110814)
22. Gasteiger J, Marsili M (1980) Iterative partial equalization of orbital electronegativity-a rapid access to atomic charges. Tetrahedron 36:3219-3228. http://www.who.int/cancer/en/
23. Iglika L, Andrew PW, Tatiana IN, John CD, Mark TDC (2006) Quantitative structure activity-activity and quantitative structure-activity investigations of human and rodent toxicity. Chemosphere 65:1878-1887
24. Karthikeyan C, Moorthy NSHN, Piyush T (2009) QSAR study of substituted 2-pyridinyl quanidine as selective urokinase-type plasminogen activator (uPA) inhibitors. J Enzyme Inhib Med Chem 24(1):6-13
25. Kolberg M, Kolberg M, Strand KR, Graff P, Andersson KK (2004) Structure, function and mechanism of ribonucleotide reductases. Biochim Biophys Acta 1699(1-2):1-34 (Pubitemid 38680791)
26. Lien EJ (1987) Ribonucleotide reductase inhibitors as anticancer and antiviral agents. Prog Drug Res 31:1-26
27. Lin A (2002) QuaSAR-descriptors. Chemical Computing Group Inc. Montreal, H3A 2R7 Canada. http://www.chemcomp.com/Journal-of-CCG/Features/descr.htm
28. Lohray BB, Gandhi N, Srivastava BK, Lohray VB (2006) 3D QSAR studies of N-4-arylacryloylpiperazin-1-yl-phenyl-oxazolidinones: a novel class of antibacterial agents. Bioorg Med Chem Lett 16: 3817-3823 (Pubitemid 44160460)
29. MOE 2007.02 (2007) Chemical Computing Group Inc., Montreal, H3A 2R7 Canada. http://www.chemcomp.com
30. Mulliken RS (1934) A new electron affinity scale; together with data on valence states and on valence ionization potentials and electron affinities. J Chem Phys 2:782-793
31. Navarra P, Preziosi P (1999) Hydroxyurea: new insights on an old drug. Crit Rev Oncol Hematol 29:249-255 (Pubitemid 29158970)
32. Neter J, Wasserman W, Kunter MH (1990) Applied linear statistical models: regression, analysis of variance, and experimental designs, 3rd edn. Irwin, Homewood, IL
33. Nocentini G(1996) Ribonucleotide reductase inhibitors: new strategies for cancer chemotherapy. Crit Rev Oncol Hematol 22:89-126 (Pubitemid 26083042)
34. Norlund P, Reichard P (2006) Ribonucleotide reductase. Annu Rev Biochem 75:681-706
35. Prasanna S, Manivannan E, Chaturvedi SC (2005) QSAR analyses of conformationally restricted 1,5-diaryl pyrazoles as selective COX-2 inhibitors: application of connection table representation of ligands. Bioorg Med Chem Lett 15:2097-2102 (Pubitemid 40445476)
36. Raichurkar AV, Kulkarni VM (2003) Understanding the antitumor activity of novel hydroxysemicarbazide derivatives as ribonucleotide reductase inhibitors using CoMFA and CoMSIA. J Med Chem 46:4419-4427 (Pubitemid 37238745)
37. Ren S, Wang R, Komatsu K, Bonaz-Krause P, Zyrianov Y, McKenna EE, Csipke C, Tokes ZA, Lien EJ (2002) Synthesis, biological evaluation, and quantitative structure-activity relationship analysis of new Schiff bases of hydroxysemicarbazide as potential antitumor agents. J Med Chem 45:410-419 (Pubitemid 34073458)
38. Robert MO (2007) A caution regarding rules of thumb for variance inflation factors. Qual Quant 41:673-690
39. Rotriquez G (1993-2000) Chapter 2, linear models for continuous data. 49-58. (http://data.princeton.edu/wws509/notes)
40. Shao J, Zhou B, Chu B, Yen Y (2006) Ribonucleotide reductase inhibitors and future drug design. Curr Cancer Drug Targets 6: 409-431 (Pubitemid 44033390)
41. Statistica 8.0 statistical software (2007) StatSoft, Inc. USA
42. Szekeres T, Fritzer-Szekeres M, Elford HL (1997) The enzyme ribonucleotide reductase: target for antitumor and anti-HIV therapy. Crit Rev Clin Lab Sci 34:503-528 (Pubitemid 28043734)
43. Tomas R, Ossama BK, Barry SC (2005) Rational representation of ribonucleotide reductase activity. BMC Biochem 6:8
44. Tropsha A, Gramatica P, Gombar VK (2003) The importance of earnest, validation is the absolute essential application and interpretation of QSPR models. QSAR Comb Sci 22:69-77 (Pubitemid 36717473)
45. Tsimberidou AM, Alvarado Y, Giles FJ (2002) Evolving role of ribonucleoside reductase inhibitors in hematologic malignancies. Expert Rev Anticancer Ther 2:437-448 (Pubitemid 34947120)